SAN DIEGO, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today provides an update on recent and upcoming scientific presentations.
Scientific Presentations
- A presentation titled “Elaborating ELAD Mechanism of Action and Linking Cell-Based Models to the Clinic” was made on September 9, 2017 at the 18th International Symposium on Albumin Dialysis 2017 in Rostock-Hohe Düne, Germany.
- A poster presentation titled “Both MELD Score and Number of Organ Failures Defined by the Latest Chronic Liver Failure-Organ Failure Scoring System Effectively Select Subjects with Severe Alcoholic Hepatitis with Good Outcomes when Treated with the ELAD® System” will be presented at the American Association for the Study of Liver Diseases (AASLD) Single Topic Conference titled “Acute on Chronic Liver Failure: Is it Ready for Clinical Practice?” taking place September 15-16, 2017 in Chicago, IL.
- A poster presentation titled “Impact of the Systemic Inflammatory Response Syndrome on 3-month Mortality Rates in Subjects with Severe Alcoholic Hepatitis Treated with the ELAD System” will also be presented at the AASLD Single Topic Conference, September 15-16, 2017 in Chicago, IL.
- An electronic poster presentation titled “Ethanol-Induced Oxidative Stress in Primary Human Hepatocytes is Suppressed by VTL C3A Cell-Secreted Factors” will be presented at the European Association for the Study of the Liver (EASL)-AASLD joint meeting “Definition, therapeutic advances and clinical endpoints in alcoholic liver disease and alcoholic hepatitis” to be held September 30-October 1, 2017 in London, United Kingdom.
Posters and associated presentations are made available at http://ir.vitaltherapies.com in the "Clinical Publications and Presentations" section promptly after they have been made publicly.
Upcoming Investor Conference
The Company will be presenting at the 2017 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2017 at 4:00 PM Eastern in New York City. A live webcast of the Company's presentation will be available on the Investor Relations page of the Company's website at: http://ir.vitaltherapies.com/. An archive of the presentation will be available for replay following the conference.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company’s ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
Contact:
Vital Therapies, Inc.
Al Kildani
Vice President, Investor Relations and Business Development
858-673-6840
akildani@vitaltherapies.com